Weight loss medications have been around for decades, but the latest generation of drugs has created a frenzy like never before. Initially developed to manage diabetes, medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have been repurposed for weight loss, with some users reporting dramatic results. These GLP-1 receptor agonists work by mimicking gut hormones that help regulate appetite and insulin levels. As their popularity reaches stratospheric levels, questions are now being asked: Are the drugs a breakthrough, or is the situation more complex?These medications work by making people feel fuller sooner and for a longer period of time. Research indicates that people on Wegovy (semaglutide) lose about 12% of their weight, while those on Zepbound (tirzepatide) lose about 18%. Besides losing weight, these drugs also appear to have other health benefits like lowering blood pressure, decreasing the risk of heart attacks and strokes, and even potentially treating neurological disorders like Alzheimer's and Parkinson's.Although these medications have promising outcomes, they do carry potential risks. The most prevalent side effects are nausea, vomiting, fatigue, diarrhea, and constipation. Although most individuals adapt to the medication with time, some develop severe reactions. There have been lawsuits filed against pharmaceutical firms by patients who suffered serious gastrointestinal disorders like stomach paralysis and bowel blockages.The other increasing concern is the psychological one. Patients are urged to stay on the drugs even in the face of adverse effects, which makes them have terrible experiences that degrade their quality of life. Consequently, a large percentage of users drop the medication within several months. A recent survey in the journal Obesity revealed that 19% of people put on these medications were still on them after a year.GLP-1 medications have been approved by the FDA only for obese patients (BMI of 30 or higher) or those with weight-related conditions such as hypertension. Yet, high demand has resulted in off-label prescribing on a large scale, with people getting them even if they do not qualify. This demand has created national shortages, and the FDA has permitted compounding pharmacies to make generic versions.Even though they work, access is not an option for most. Insurance only covers them minimally, and Medicare will only pay for weight loss medication if it is for diabetes. With the average cost being $1,300 per month, people from low-income communities, statistically with higher obesity rates, can't afford these drugs.Weight Loss Drugs: Expectations vs. RealityAlthough these drugs are beneficial for one's health, their use in cosmetic weight loss has also come into limelight. Social media is full of sensationalized "before and after" pictures, which create unrealistic hopes. But the so-called "Ozempic face" has been a harsh reminder that weight loss is not necessarily translated into a healthier and younger looks.Do You Have to Take These Weight Loss Medications Forever?One of the most contentious issues with GLP-1 medications is the long-term commitment they necessitate. Recent studies suggest that those who stop taking these medications tend to regain the weight lost. The human body, evolved over time, is programmed to store fat effectively—rendering long-term weight loss a life-long struggle for many.While lifestyle changes like diet and exercise are crucial aspects of weight control, they're usually not enough by themselves for people with obesity. The question is: Are these drugs a short-term solution, or are they a lifetime solution? And more so, should patients be required to continue taking them for the rest of their lives to keep the weight off?Do You Have to Take These Weight Loss Drugs Forever?GLP-1 drugs have unquestionably revolutionized the weight loss scenario, giving hope to millions. Yet, they are far from a silver bullet. The cost, access concerns, side effects, and long-term dependence are all valid issues. Although they do possess undeniable advantages, their efficacy and sustainability are based on the patient's capacity to follow the regimen and accept possible risks.Before they decide, people need to balance the pros against the cons and seek the advice of healthcare professionals to see whether these drugs fit into their health agenda. As science continues to develop, the future of GLP-1s is potentially even brighter—but for now, they are both a revolutionary solution and a highly contentious issue in the battle against obesity.What's Next for Weight Loss Drugs Worldwide?While pharmaceutical manufacturers continue to innovate and perfect weight loss drugs, future research will be what decides their long-term effect. US pharma major Eli Lilly launched the much-awaited diabetes and obesity management drug Mounjaro in India on Thursday at one-fifth of the US price. With obesity rates rising in India, the market for weight loss drugs has grown exponentially in the country. Novo Nordisk's oral semaglutide tablet, Rybelsus, launched in India in January 2022, has already captured nearly 65 per cent of the anti-obesity drugs market, which includes other weight-loss medications such as dulaglutide, orlistat, and liraglutide.